Spero Therapeutics (NASDAQ:SPRO) issued its earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.15, Fidelity Earnings reports. Spero Therapeutics had a negative return on equity of 52.22% and a negative net margin of 1,402.91%. The company had revenue of $1.69 million for the quarter, compared to analyst estimates of $0.84 million.
Shares of NASDAQ:SPRO traded down $0.01 during trading on Friday, reaching $12.97. 22,979 shares of the stock were exchanged, compared to its average volume of 64,938. Spero Therapeutics has a 1-year low of $5.52 and a 1-year high of $19.00. The firm has a market capitalization of $223.16 million, a price-to-earnings ratio of -0.73 and a beta of 2.96.
SPRO has been the topic of a number of research reports. Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Saturday, January 5th. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research report on Sunday, January 13th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, February 26th. Finally, ValuEngine lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Spero Therapeutics presently has an average rating of “Hold” and an average price target of $20.65.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
See Also: Diversification Important in Investing
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.